PRESS RELEASE: 26 February 2019, 07:00 CET
Biocartis Places Its 1,000th Idylla(TM) Instrument with Geisinger in US
Mechelen, Belgium, 26 February 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it has placed its 1,000th Idylla(TM) instrument. The instrument was placed in the US with Diagnostic Medicine Institute at Geisinger.
The Geisinger Medical Center in Danville, Pennsylvania (US) is one of the main hospitals in the Geisinger group which covers 13 hospital campuses, two research centers and close to 30 specialties, including an advanced cancer institute in the Pennsylvania and New Jersey regions. Geisinger is one of the largest health service organizations in the US, serving millions of patients throughout Pennsylvania and New Jersey[1].
Herman Verrelst, CEO Biocartis, commented: "We are very proud that we could place our 1,000th Idylla(TM) instrument with Geisinger which is one of the leading oncology practices in the US and an important business partner for Biocartis going forward. Crossing the 1,000 mark is an important milestone in the global commercial roll-out of the Idylla(TM) platform and further strengthens our position in partnership discussions."
Yi Ding, M.D., Ph.D., System and Core Lab Director, Diagnostic Medicine Institute at Geisinger, reacted: "Oncology is one of the key specialist areas for Geisinger, with the Diagnostic Medicine Institute at Geisinger being a leader in precision medicine. We are excited about using the Idylla(TM) technology as it is fast and easy to use and delivers highly accurate results."
----- END ----
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. The Biocartis trademark and logo and the Idylla(TM) trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.